The 200,000 sq. ft. space consolidates elements of Moderna’s development, operations and nearly 200 employees under one roof
DPS Group and design affiliate TRIA have completed a new 200,000 square foot cGMP mRNA clinical manufacturing facility for Moderna Therapeutics.
DPS and TRIA provided full architectural, engineering design, and project management services for the new clinical development manufacturing facility located at One Upland Road in Norwood, Mass. The facility’s official opening was marked by a ribbon cutting ceremony held on July 17th.
Moderna’s Norwood facility provides the capacity to develop materials for pre-clinical toxicology studies, as well as Phase 1 and Phase 2 clinical development programs. It also has the capability to support new medicines enabled by Moderna’s mRNA platform.
“Our Norwood site gives us capability to manufacture materials for our pre-clinical and early-stage development programs for our portfolio of mRNA development candidates,” said Steve Harbin, Moderna’s Norwood manufacturing site lead. “DPS Group brought a tremendous depth of cGMP facility design experience to this ambitious project, and TRIA’s lab and workplace design expertise helped us to create an innovative work environment for our employees. With the completion of this facility, we have taken an important step in our efforts to advance new mRNA-based medicines and support our robust pipeline.”
DPS Group chief executive Frank Keogh said, “We are delighted to have worked with Moderna to bring this new state-of-the-art facility for the research and manufacture of a new generation of transformative medicines to completion. This project drew on all of the engineering, architectural and project management skills that DPS has developed in the USA since we first established here seven years ago.”
